Top

Osteoporosis International

Published in:

01-10-2007 | Original Article

Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world

Authors: H. Ideguchi, S. Ohno, H. Hattori, Y. Ishigatsubo

Published in: Osteoporosis International | Issue 10/2007

Abstract

Summary

The real cumulative persistence probabilities with bisphosphonates after 5 years was 51.7%. Prescriptions by specialists other than gynecologists and rheumatologists (p < 0.001), male sex (p < 0.001), older age (≥65 years) (p = 0.001), and cyclical etidronate (p < 0.001) were significantly associated with low persistence. Success rates of switching bisphosphonate were 75.6%.

Introduction

Many patients discontinue daily bisphosphonate therapy prematurely due to the stringent dosing procedures and adverse events. Consequently, some patients are receiving two or more sequential bisphosphonates in daily practice. Our objective was to study factors associated with the real cumulative persistence with bisphosphonate therapy including treatment courses with multiple sequential drugs in the real world setting.

Methods

We retrospectively analyzed 1,307 patients (male 197, female 1110) newly prescribed with bisphosphonates between January 1, 2000, and June 30, 2005.

Results

The real cumulative persistence probabilities with bisphosphonates after 1, 3, and 5 years were 74.8%, 60.6%, and 51.7%, respectively. Switching of bisphosphonates was observed 168 times in 146 patients. Adverse events occurred 126 times in 124 patients including 86 events with gastrointestinal complaints. Univariate analysis showed that prescriptions by specialists other than gynecologists and rheumatologists (p < 0.001), male sex (p < 0.001), older age (≥65 years) (p = 0.001), and cyclical etidronate (p < 0.001) were significantly associated with low persistence. Success rates of switching bisphosphonate were 75.6%.

Conclusions

Switching of bisphosphonates was not uncommon. Despite switching bisphosphonates to improve persistence, the real cumulative persistence with bisphosphonate was suboptimal, especially among patients of certain physician specialties and male sex.

McClung MR (2000) Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother 1:225–238PubMedCrossRef

Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199PubMedCrossRef

Gold DT, Alexander IM, Ettinger MP (2006) How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother 40:1143–1150PubMedCrossRef

McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMedCrossRef

Papaioannou A, Ioannidis G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M et al (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808–813PubMedCrossRef

Emkey RD, Ettinger M (2006) Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 119:S18–S24PubMedCrossRef

Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645–1652PubMedCrossRef

Curtis JR, Westfall AO, Allison JJ, Freeman A, Saag KG (2006) Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 17:1268–1274PubMedCrossRef

Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216PubMedCrossRef

10.

Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921PubMedCrossRef

11.

Cramer JA, Silverman S (2006) Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 119:S12–S17PubMedCrossRef

12.

Cryer B, Bauer DC (2002) Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 77:1031–1043PubMedCrossRef

13.

Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259–262PubMed

14.

Pickney CS, Arnason JA (2005) Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int 16:1156–1160PubMedCrossRef

15.

Curtis JR, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A et al (2005) Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 52:2485–2494PubMedCrossRef

16.

Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM (2006) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28:236–242PubMedCrossRef

17.

Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570–578PubMedCrossRef

18.

Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H et al (2002) A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 13:971–979PubMedCrossRef

19.

Mersfelder T, Armitstead JA, Ivey MF, Cedars M (1999) A medication use evaluation of alendronate: compliance with administration guidelines. Pharm Pract Manag Q 18:50–58PubMed

20.

Tanaka I, Hayakawa K, Oshima H (2003) Tolerance of alendronate in patients with osteoporosis. Osteoporosis Jpn 11:252–255

21.

Naito H (2006) The Japanese health-care system and reimbursement for dialysis. Perit Dial Int 26:155–161PubMed

22.

Yoshida M, Takada T, Kawarada Y, Hirata K, Mayumi T, Sekimoto M et al (2006) Health insurance system and payments provided to patients for the management of severe acute pancreatitis in Japan. J Hepatobiliary Pancreat Surg 13:7–9PubMedCrossRef

Title: Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world
Authors: H. Ideguchi
S. Ohno
H. Hattori
Y. Ishigatsubo
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 10/2007
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-007-0406-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2007

Muscle mass deficits are associated with bone mineral density in men with idiopathic vertebral fracture

Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study

Back extensor strength and lumbar spinal mobility are predictors of quality of life in patients with postmenopausal osteoporosis

Standardised quantitative morphometry: a modified approach for quantitative identification of prevalent vertebral deformities

Simple, novel physical activity maintains proximal femur bone mineral density, and improves muscle strength and balance in sedentary, postmenopausal Caucasian women

Effect of low-intensity back exercise on quality of life and back extensor strength in patients with osteoporosis: a randomized controlled trial